The Preclinical in-vivo imaging market in North America was estimated at USD 307.18 Million in 2022. It is projected to reach USD 390.18 Million by 2027, at a CAGR of 4.90% during the forecast period from 2022 to 2027.
The North America preclinical in-vivo imaging market is expected to be growing due to several factors, including technological advancements in the field of molecular imaging, rising market demand for non-invasive small animal imaging techniques, rising demand for non-invasive imaging techniques, and government support for research and development activities and an increase in the number of public-private initiatives and funding to support preclinical research. The demand for preclinical in-vivo imaging modalities is increasing in various industries, including research and development, drug discovery, cancer cell detection, and others. As a result of the growing number of clinical research organizations and pharmaceutical companies, in-vivo imaging technologies are being more widely used in preclinical research, propelling the market's growth.
Some of the primary factors restraining the growth of the Preclinical in-vivo Imaging market in the North American region include a rigorous regulatory framework that controls preclinical research, high product prices, and considerable installation and operational expenses associated with preclinical imaging modalities. Furthermore, standalone systems' technological and operational constraints pose a significant challenge for participants in the North American Preclinical in-vivo Imaging market.
This research report on the North America preclinical in-vivo imaging market has been segmented and sub-segmented into the following categories:
Regionally, North America holds the largest share of the global preclinical imaging market, while the U.S. has the maximum share in North America. The preclinical imaging market in North America is primarily driven by factors like a high volume of preclinical research in this region, easy availability and accessibility of resources, and rising government funding for research and innovation in Canada.
The expansion of the preclinical in-vivo imaging market in the United States is being accelerated by rising research and development funding and the availability of well-developed research infrastructure. Market participants are also collaborating with distributors to expand their product reach. For example, Aspect Imaging, a market leader in the design and development of compact magnetic resonance systems for preclinical, medical, and industrial applications announced in September 2017 that Quantum Analytics would be its exclusive US distributor for its Industrial product portfolio. A well-developed research infrastructure, the availability of trained personnel, a significant number of Preclinical projects, and more excellent adoption rates of technically advanced devices in the region are the primary drivers of the Preclinical In-vivo imaging market in North America. Furthermore, government activities in the region foster new clinical research and development projects.
The Canadian R&D tax credit scheme is an example of a government policy promoting the country's R&D activities. The Preclinical in-vivo imaging market benefits from government support in the form of funding and tax incentives. In light of all considerations, North America is expected to maintain its supremacy for the duration of the forecast period.
KEY MARKET PLAYERS:
Companies playing a dominant role in the North America Preclinical in-vivo imaging market profiled in this report are Aspect Imaging, Biospace Lab S.A., Bruker Corporation, LI-COR Biosciences, Mediso Ltd., MILabs B.V., MR Solutions Ltd, PerkinElmer, Inc., TriFoil Imaging, and FUJIFILM VisualSonics, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com